{"schema_version":"secwatch.filing_event.v1","accession":"0001804585-23-000007","form_type":"8-K","ticker":null,"cik":"0001804585","company_name":"NUGENEREX IMMUNO-ONCOLOGY, INC.","filed_at":"2023-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.676083+00:00","generated_at":"2026-06-17T04:41:15.997593+00:00","sec_items":["5.01","5.07","8.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Beijing Youfeng acquires 64% of NuGenerex for $3.35M in bankruptcy; new board and CEO appointed","bullets":["Beijing Youfeng Biological Technology acquired 64,153,151 common shares (63.96%) and 100% of Series A Super Voting Preferred on March 3, 2023 for $3.35 million.","Control assumed from Chapter 7 Trustee Marc P. Barmat of Generex Biotechnology's bankruptcy estate.","On March 15, 2023, majority shareholder elected new directors: XiaoYan Wang, Feng Wang, and Kevin McGovern via written consent.","New board on March 21, 2023 removed all officers except Dr. Eric von Hofe; appointed Feng Wang as CEO, Secretary, Treasurer; von Hofe as President and CSO."],"urls":{"canonical":"https://secwatch.observer/filing/0001804585-23-000007","json":"https://secwatch.observer/filing/0001804585-23-000007.json","markdown":"https://secwatch.observer/filing/0001804585-23-000007.md","text":"https://secwatch.observer/filing/0001804585-23-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1804585/000180458523000007/0001804585-23-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1804585/000180458523000007/plain8k.txt"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T04:41:15.997593+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e278a6a13761df1444322892a74308d1dbfac373","claim":"NUGENEREX IMMUNO-ONCOLOGY, INC. underwent a change of control involving Beijing Youfeng Biological Technology Co., Ltd. for $3.35 million (closed 2023-03-03).","evidence_excerpt":"District of Florida, Fort Lauderdale Division on February 7, 2023, Beijing Youfeng Biological Technology Co., Ltd. and the Chapter 7 Trustee allocate the purchase price of $3.35 million for the equity and assigned claims of Generex Biotechnology Corporation such as they agree. (5) the source(s) of funds used by the person(s); and (6) the identity of the","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1804585/000180458523000007/0001804585-23-000007-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Beijing Youfeng Biological Technology Co., Ltd."},{"label":"Consideration","value":"$3.35 million"},{"label":"Closing","value":"2023-03-03"}],"fact_type":"ma_transaction"},{"claim_id":"0376178b4eebc17a23321d1c936d84573beb044b","claim":"NUGENEREX IMMUNO-ONCOLOGY, INC. shareholders approved Election of directors by written consent of majority shareholder at the 2023-03-15 meeting.","evidence_excerpt":"XiaoYan (Maggie) Wang, Feng (Anthony) Wang and Kevin McGovern were elected as the new directors of NGIO without a meeting, through the written consent of the majority shareholder dated March 15, 2023","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1804585/000180458523000007/0001804585-23-000007-index.htm","confidence":0.7,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-03-15"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}